eli lilly retatrutide trials ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Eli Lilly's Retatrutide Clears Two

Currently, there are limited clinical trials evaluating the efficacy of these two drugs in MASLD

Additional important aspects are the benefits of increased levels of E

It effectively lowers A1c levels, an important indicator of long-term blood sugar control, and also helps manage postprandial and fasting blood glucose levels

The glucagon receptor agonism, whilst counterintuitive given glucagon's role in raising blood glucose, is thought to increase energy expenditure and promote hepatic fat oxidation whilst reducing lipogenesis effects that may offer potential benefits in metabolic dysfunction-associated steatotic liver disease (MASLD)

They are designed to do everything the GLP-1 hormone does, but they last longer

And TRANSCEND-T2D-1, part of a separate three-trial diabetes-specific program, confirmed -2.0% HbA1c reduction and 16.8% weight loss in 537 type 2 diabetes patients (topline March 2026, published in The Lancet, June 2026)